Preliminary imaging and therapy study of <sup>131</sup>I-hTgMcAb in thyroid cancer metastasis which can not accumulate <sup>131</sup>I

GAO Kejia1 SHEN Jiangfan2 ZHANG Naikang2 TAO Rong2 WANG Jianhua1 YE Zhiwei1     ZHAO Linmei1 ZHANG Guangzheng2 MA Jixiao3     1

doi:null

您当前的位置：

首页 >

文章列表页 >

Preliminary imaging and therapy study of ¹³¹I-hTgMcAb in thyroid cancer metastasis which can not accumulate ¹³¹I

更新时间：2021-03-12

- Preliminary imaging and therapy study of ¹³¹I-hTgMcAb in thyroid cancer metastasis which can not accumulate ¹³¹I
- NUCLEAR TECHNIQUES Issue 1, (2005)
- 作者机构：
  
  1. 上海市黄浦区中心医院核医学科
  2. 上海市普陀区中心医院核医学科
  3. 上海市第六人民医院核医学科,上海,200002
  4. ,上海,200233
- 作者简介：
- 基金信息：
- DOI：
  CLC： R736.1
- Published：01 January 2005
- 稿件说明：
移动端阅览
[1]高克加,沈江帆,张乃康,陶嵘,王建华,叶智卫,赵林妹,张光正,马寄晓.不能摄取~(131)I的甲状腺癌转移灶的~(131)I-hTgMcAb显像及初步治疗[J].核技术,2005(01):46-50.

GAO Kejia1 SHEN Jiangfan2 ZHANG Naikang2 TAO Rong2 WANG Jianhua1 YE Zhiwei1 ZHAO Linmei1 ZHANG Guangzheng2 MA Jixiao3 1. Preliminary imaging and therapy study of ¹³¹I-hTgMcAb in thyroid cancer metastasis which can not accumulate ¹³¹I[J]. Nuclear techniques, 2005, (1): 46-50.
[1]高克加,沈江帆,张乃康,陶嵘,王建华,叶智卫,赵林妹,张光正,马寄晓.不能摄取~(131)I的甲状腺癌转移灶的~(131)I-hTgMcAb显像及初步治疗[J].核技术,2005(01):46-50. DOI：

GAO Kejia1 SHEN Jiangfan2 ZHANG Naikang2 TAO Rong2 WANG Jianhua1 YE Zhiwei1 ZHAO Linmei1 ZHANG Guangzheng2 MA Jixiao3 1. Preliminary imaging and therapy study of ¹³¹I-hTgMcAb in thyroid cancer metastasis which can not accumulate ¹³¹I[J]. Nuclear techniques, 2005, (1): 46-50. DOI：

摘要

对不能摄取I的分化型、低分化型和未分化型甲状腺癌转移灶患者

采用I-hTgMcAb进行显像和131初步治疗

观察诊断转移灶和治疗价值。动物实验取无菌、无致热源的I-hTgMcAb

18.5MBq（131I）/50μg131（hTgMcAb）/kg静脉注射于新西兰实验兔

观察一个月

了解I-hTgMcAb的稳定性、安全性及体内代谢。131临床诊断26例上述各型甲状腺癌转移患者静脉滴注I-hTgMcAb稀释液。经多时相SPECT显像测定肿瘤与131正常组织之比（T/N）。分析治疗后4个月的I显像、X片、99mTc-MIBI显像等进行疗效对照及随访肝肾功131能、血常规、血小板、出、凝血时间。实验兔在静脉注射后6h内显像

见心腔、大血管显影

隐见肝区显影

但未见甲状腺、胃显影。经显像及治疗的26例甲状腺癌转移者I-hTgMcAb不同程度地浓聚于X摄片或CT131定位的转移灶部位

未感不良反应。131I-hTgMcAb进入转移灶的最高峰时间在72h左右。有5例患者的转移灶轻度缩小

17例患者的转移灶未见增大或增多。动物试验提示131I-hTgMcAb稳定性较好

未见有明显的毒性反应。对了解甲状腺癌转移灶的存在与治疗有一定的临床应用价值。

Abstract

Aim of this work is to evaluate the diagnostic and prospective value of 131I-hTgMcAb for the differential

low differential and other type of thyroid cancer which do not uptake 131I. New Zealand rabbits were IV with asepsis and pyrogen-free 131I-hTgMcAb (18.5 mBq/kg) in order to study the stability

safety and metabolism in vivo. 26 cases of thyroid cancer with metastasis were IV 131 I-hTgMcAb. Multiple-phase SPECT imaging was done and the radioactive ratios of T/N were determined. We compared the 131I imaging

X-ray photos

99mTc -MIBI imaging before and after 4 month therapy to evaluate the therapy effect. The liver and kidney function was followed up. The animal experiment showed that the cardiac chambers and great blood vessels could be imaged in 6 h

the liver was faintly visualized

while thyroid and stomach were not displayed. 26 cases showed 131I-hTgMcAb accumulated in the metastasis lesions which were identified by X-ray films or CT studies. The peak uptake time is about 72 h

the T/N ratio is over 4. After 4 months follow-up

the lesions of 5 cases became smaller

no changes in 17 cases. It is concluded that the stability of131I-hTgMcAb is good

no obvious side effects are found

so 131I-hTgMcAb is helpful to localize and treat the thyroid cancer.

关键词

Keywords

references

Views

117

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Study on the whole body distribution of ⁹⁹Tc^m-angiostatin and its effect on novel blood vessel

Progress of ligands for imaging nicotinic acetylcholine receptor (nAChRs)

(67)^Ga lung tumor imaging and its clinical value

Related Author

TAO Yonghui1 ZHANG Lianfen1 YOU Xuyang2 WAN Weixing2 JIN Jian1 1

张莲芬

尤徐阳

万卫星

金坚

LIU Yuxia LIU Ning LIAO Jiali

刘宁

廖家莉

Related Institution

The Key Laboratory of Industrial Biotechnology, Ministry of Education, Southern Yangtze University, Wuxi 214036, China) 2

苏州大学附属第四医院

Key Laboratory of Radiation Physics and Technology, Education Ministry of China, Institute of Nuclear Science and Technology, Sichuan University

辐射物理及技术教育部重点实验室

AI问答

Address：2019 Jialuo Road, Jiading, Shanghai, China Postal code：201800
Tel：021-39194977 Email：LHB@sinap.ac.cn
Technical support is provided by Beijing Founder electronics co., LTD 沪ICP备05005479号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
Total Visits：881077 Visits Today：604

⁰

Preliminary imaging and therapy study of 131I-hTgMcAb in thyroid cancer metastasis which can not accumulate 131I

DOI：

摘要

Abstract

关键词

Keywords

references

Preliminary imaging and therapy study of ¹³¹I-hTgMcAb in thyroid cancer metastasis which can not accumulate ¹³¹I